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H I G H L I G H T S
• Race and body mass index interact in high grade endometrial carcinoma survival.
• Comorbidities negatively impact high grade endometrial cancer survival.
• Guideline-concordant treatment decreases hazard of endometrial carcinoma death.
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a b s t r a c t
Objective. To estimate overall survival, disease-speciﬁc survival, and progression-free survival among high
grade endometrial carcinoma cases and to determine factors impacting survival for non-Hispanic white and
non-Hispanic black women.
Methods. We identiﬁed high grade endometrial carcinoma cases among non-Hispanic white and nonHispanic black women from ongoing institutional studies, and determined eligibility through medical record
and pathologic review. We estimated effects of demographic and clinical variables on survival outcomes using
Kaplan Meier methods and Cox proportional hazards modelling.
Results. Non-Hispanic Black women with BMI <25.0 had poorest overall survival compared to non-Hispanic
white women with BMI <25.0 (HR 3.03; 95% CI [1.35, 6.81]), followed by non-Hispanic black women with BMI
25.0+ (HR 2.43; 95% CI [1.28, 4.60]). A similar pattern emerged for disease-speciﬁc survival. Non-Hispanic black
women also had poorer progression-free survival than non-Hispanic white women (HR 1.40; 95% CI [1.01, 1.93]).
Other signiﬁcant factors impacting survival outcomes included receipt of National Cancer Center Network
(NCCN) guideline-concordant treatment (GCT), earlier stage at diagnosis, and fewer comorbid conditions.
Conclusions. BMI and race interact and modify the association with high grade endometrial carcinoma survival. Other potentially modiﬁable factors, such as reducing comorbidities and increasing access to GCT will potentially improve survival after diagnosis of high grade endometrial carcinomas. A better understanding of the
molecular drivers of these high grade carcinomas may lead to targeted therapies that reduce morbidity and mortality associated with these aggressive tumors.
© 2021 Elsevier Inc. All rights reserved.

1. Introduction
Endometrial carcinoma is the most common gynecological cancer in
the United States, and the American Cancer Society estimates that there
were approximately 65,600 new cases of endometrial cancer in the US
⁎ Corresponding author at: 4100 John R St, Mailcode MM04EP, Detroit, MI 48201, USA.
E-mail address: cotem@karmanos.org (M.L. Cote).

in 2020 [1]. Incidence rates of endometrial cancer have been rising for
decades, from 23.7 per 100,000 in 2000 to 27.2 per 100,000 in 2017,
and are projected to continue rising [2,3]. Incidence rates were previously thought to be highest among non-Hispanic white (NHW)
women; however, once corrected for hysterectomy status, incidence
rates of endometrial cancer are substantially higher among nonHispanic black (NHB) women [4,5]. From 2012 to 2014, hysterectomycorrected incidence rates of endometrial cancer were estimated at 102
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We identiﬁed a total of n = 601 women with high grade endometrial cancers (stages I-III) who underwent a hysterectomy at KCI and
HFHS between 1998 and 2017. Upon re-review of existing slides and
corresponding tissue blocks, n = 185 (30.8%) were excluded for the following reasons: low grade (n = 81, 43.8%), no tumor or microscopic
(n = 70, 37.8%), could not locate blocks (n = 23, 12.4%) or other reasons
(n = 23, 12.4%). It should be noted that the large number excluded due
to being of low grade does not imply that the initial report was incorrect,
it could simply be that the remaining blocks did not have high grade
areas, as grade is not uniform across the tumor landscape. Of the
n = 416 remaining, n = 34 (8.1% of the re-conﬁrmed high grade tumors) were excluded from the current analysis for various reasons, including death within 2 months, stage IV disease, or unknown stage.
Demographic and clinical data on patients were abstracted from the
MDCSS, Detroit Medical Center (DMC), KCI, or HFHS electronic health
records, spanning from 1997 to 2017. This study was approved by the
Wayne State University Institutional Review Board (043116M1E).
Study variables included age at diagnosis, marital status, percentage
of census tract in poverty, FIGO stage, histology, Body Mass Index
(BMI) at diagnosis, comorbidity burden as measured by the Charlson
Comorbidity Index, hypertension, and National Comprehensive Cancer
Network (NCCN) guideline-concordant treatment. NCCN guidelineconcordant treatment (NCCN GCT) was deﬁned as a patient receiving
treatment as speciﬁed by NCCN guidelines for that year, stage, and histology [13–16]. Patients receiving treatment more aggressive than recommended by NCCN were also considered guideline-concordant, with
those who received less aggressive treatment than recommended by
NCCN guidelines were considered not guideline-concordant. The “lead
time” for adjuvant therapy was deﬁned as the time between hysterectomy date and ﬁrst adjuvant therapy treatment date (presented in
months). Other categorized variables included BMI (<25.0 and
25.0+), and comorbidity count (0, 1, 2, and 3 or more; based on comorbidities included in the Charlson Comorbidity Index) [17]. Age at diagnosis was categorized (<50, 50–59, 60–69, and 70+) for use in model
stratiﬁcation.
Three different outcomes were assessed: overall survival, endometrial carcinoma survival accounting for the competing risk of other
causes of death, and progression-free survival. Survival times were calculated from hysterectomy date to date of event or last follow-up. The
outcomes were abstracted from medical records and deaths were conﬁrmed via MDCSS and vital records. Endometrial carcinoma death was
determined using the primary cause of death coded from the death certiﬁcate in the MDCSS database (ICD-10 codes: C53-C56) or from medical records. Recurrence status, used in the progression-free survival
model, was ascertained through medical records by a trained SEER program abstractor. Cases were determined to be “never disease-free”
when medical records indicated evidence of continued disease and/or
treatment throughout the patient's survival time.

per 100,000 NHB women, compared to 86 per 100,000 NHW women
[4]. Endometrial carcinoma also has one of the highest survival disparities in cancer, with consistent estimates over the last several decades
reporting that NHB women are 80% more likely to die from this disease
compared to NHW women [5,6].
Among endometrial carcinomas, the low grade endometrioid histologic subtype is the least aggressive and most common [7]. Rates of this
subtype remained mostly stable for NHW women from 2000 to 2015,
while rates of endometrioid subtype in racial and ethnic minorities,
and rates of non-endometrioid subtypes for all women, increased substantially [8]. Non-endometrioid histologic subtypes, such as clear cell,
serous, and carcinosarcoma, are usually classiﬁed as high grade, are
more commonly diagnosed in NHB women, and have worse outcomes
and survival [8,9]. Among endometrial cancer cases registered by the
Surveillance, Epidemiology, and End Results (SEER) program from
2000 to 2011, 36% of NHB cancers were high grade, compared to 21%
of NHW cases [10]. While NHB women are more likely to be diagnosed
with these more aggressive subtypes [11], it doesn’'t entirely account for
the survival disparity [10]. Literature exploring the endometrial cancer
survival disparity often considers race only a biological construct, rather
than as a proxy for modiﬁable contributors to racial disparities, such as
treatment inequity and the importance of early diagnosis [12].
Many epidemiologic studies of endometrial cancer do not have adequate numbers of non-white women [5], and many studies combine
high and low grade cancers. Thus, most of our knowledge surrounding
endometrial cancer incidence and survival from an epidemiologic perspective is based on low grade, endometrioid tumors in NHW women.
As high grade tumors are more aggressive, and result in the greatest
morbidity and mortality from this disease, research speciﬁcally focused
on these endometrial cancer types is needed. Here, we estimated overall
survival, disease-speciﬁc survival, and progression free survival, including clinical and demographic factors that may impact survival after a diagnosis of high grade endometrial carcinoma in NHB and NHW women
from two large, urban medical centers. We hypothesized that after adjustment for individual-level variables, the higher risks of death
among NHB women with high grade endometrial carcinomas seen in
population-based studies would be attenuated.

2. Methods
2.1. Case identiﬁcation
Potential cases were identiﬁed from ongoing observational studies
(housed in radiation oncology at Henry Ford Health System and pathology at Karmanos Cancer Institute), and supplemented with data from
the Metropolitan Detroit Cancer Surveillance System (MDCSS). The
MDCSS has continuously provided active identiﬁcation and follow up
of malignant tumors diagnosed in all residents of Wayne, Macomb,
and Oakland counties of Michigan since 1973 as one of the founding
registries in the Surveillance, Epidemiology and End Results program.
Here, eligible cases included NHB and NHW women, ages 21–79 at diagnosis, diagnosed with International Federation of Gynecology and Obstetrics (FIGO) 2009 stage I-III, and received a hysterectomy at Henry
Ford Health System (HFHS) or Karmanos Cancer Institute (KCI) with
or without adjuvant therapies. Grade and histological subtype were
reviewed by a gynecologic pathologist (RAF). Clear cell, serous, highgrade endometrioid, and mixed tumors were included. As access to
tumor tissue was crucial to the goal of the parent study, as part of the inclusion criteria women had to have undergone surgical treatment as
part of their primary course of therapy, which excluded the majority
of the women with stage IV disease at diagnosis. Thus, we made the decision to limit the study cohort to women with stages I-III. Similarly,
given that carcinosarcomas are a mixture of cell types from the inner
lining endometrium and the outer muscles, our pathologists recommended excluding this subtype a priori.

2.2. Statistical analysis
Statistical analyses were performed with SAS 9.4 (Cary, NC), ﬁgures
were produced with R (version 4.0, © 2009–2020 R Studio; packages:
survival, cmprsk, and survminer), and an alpha of 0.05 was considered
statistically signiﬁcant. The distribution of demographic and clinical variables were compared between NHW and NHB cases using chi square
tests for categorical variables, Cochran-Armitage tests for ordinal variables, and Wilcoxon rank-sum tests for continuous variables. The
Kaplan Meier method was used to calculate median overall and
progression-free survival, along with corresponding plots. Cox proportional hazards regression was used to estimate the hazards associated
with overall survival and progression-free survival. Competing risks regression using the Fine-Gray test of signiﬁcance testing structure was
used to analyze endometrial cancer survival with competing risk of
other cause of death. Hazard ratios (HR) and 95% conﬁdence intervals
(95% CI) were reported.
2
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The Cox model for overall survival was developed by ﬁrst including
all variables of interest, then excluding variables individually by highest
p-value until all remaining variables were statistically signiﬁcant. Variables were then individually reintroduced into the model to check for
changes in beta estimates of 10% or more. Models were stratiﬁed by
age group at diagnosis and treatment site, to account for the expectation
of different baseline hazards among these subgroups. Interaction effects
between factors were investigated.
The same ﬁnal set of variables were utilized for the endometrial
cancer-speciﬁc survival model to allow for direct comparisons of predictive variables, but includes competing risk of other cause of death.
The Cox model for progression-free survival was developed in the
same manner as the model for overall survival, using the same strata
to allow for varying baseline hazards. Variables were individually excluded by highest p value, and added back in to check for changes in
beta estimates after the model included only signiﬁcant variables.

diagnosis more than doubled hazard of endometrial cancer death (HR
2.44; 95% CI [1.40, 4.24]) when compared to stage I patients, and hazard
of endometrial cancer death was more than quadrupled in stage III patients (HR 4.52; 95% CI [3.04, 6.72]). Each additional comorbidity
corresponded with a 16% higher hazard of endometrial cancer death
on average (HR 1.16; 95% CI [1.03, 1.31]).
In the Cox proportional hazards model for progression-free survival,
race was a statistically signiﬁcant predictor, with NHB women having a
40% higher hazard of disease progression (HR 1.40; CI [1.01, 1.93]) compared to NHW women after stratiﬁcation by age group and treatment
site, and adjustment for stage at diagnosis, histology type, NCCN GCT,
comorbidity count, and BMI category (Table 3). Patients who were
stage III at diagnosis had 2.73 times the hazard of progression of stage
I patients (CI [1.97, 3.79]). Comorbidity count was also a statistically signiﬁcant predictor of progression, with an addition of one comorbidity
corresponding with a 17% higher hazard of progression on average
(HR 1.17; CI [1.06, 1.30]). Not receiving NCCN GCT more than doubled
the hazard of progression (HR 2.24; CI [1.26, 4.00]), while histology
and BMI were not predictive of progression-free survival.

3. Results
Of the 382 high grade endometrial carcinoma cases, 40.1% were
NHW, and 59.9% NHB, and there were signiﬁcant demographic differences between these women (Table 1). NHB women had different distributions of age group at diagnosis, marital status, and percentage of
census tract in poverty when compared to NHW women. Less than 6%
of NHB women were diagnosed younger than age 50, compared to
13.1% of NHW women. NHB women also had higher frequencies of
being divorced, separated, or widowed (48.0% compared to 23.7% of
NHW; global p < 0.001), and of living in a census tract with 20% or
more poverty (71.6% compared to 19.6% NHW; p for trend <0.001).
Differences by race were also seen in medical history, with statistically signiﬁcant differences in distribution of BMI, number of comorbidities, and hypertension. NHB women had a higher frequency of BMI over
25.0 (88.7% versus 77.8%; p = 0.003), having 3 or more comorbidities
(16.3% versus 7.2%; p < 0.001), and 83.7% of NHB women had hypertension, compared to 60.5% of NHW women (p < 0.001). NHB and
NHW women had a very similar distribution of stage at diagnosis
(p = 0.17). As for histology, nearly 50% of NHW women were diagnosed
with an endometrioid adenocarcinoma, compared to 29.7% of NHB
women. Serous cell carcinoma was the predominant subtype among
NHB women (54.2%). The two groups did have similar frequencies of
the less common mixed cell and clear cell subtypes, but overall distributions of histologic subtypes were signiﬁcantly different by race
(p < 0.001).
While 93.9% of NHB patients received NCCN guideline-concordant
treatment (GCT) compared to 91.5% of NHW women, NHB patients' median survival time was 4.7 years compared to NHW patients' 6.7 years.
Both overall survival and progression-free survival showed signiﬁcant
differences in unadjusted survival by race (Figs. 1 and 2; log-rank
p values = 0.008 and 0.003, respectively).
The interaction between race and BMI was a signiﬁcant predictor for
overall survival in both the Kaplan Meier unadjusted survival curve
(Fig. 3) and the multivariable Cox proportional hazards model
(Table 2); NHB women with BMI <25.0 had 3 times the hazard of
death of NHW women with BMI <25.0 [HR 3.03; CI (1.35, 6.81)].
Other signiﬁcant predictors that increased hazard of death included comorbidity count, not receiving NCCN guideline-concordant treatment,
and later FIGO stage at diagnosis. The only histologic subtype that significantly impacted survival was the clear cell subtype, which halved hazard of death relative to the endometrioid subtype [HR 0.43, 95% CI (0.21,
0.85)].
The race/BMI interaction was also a signiﬁcant predictor for endometrial carcinoma-speciﬁc survival with competing risk of other causes
of death (Model 2; Table 2; Supplementary Fig. S1). NHB women with
BMI <25.0 again had elevated hazard of death compared to white
women in both BMI categories (HR 3.23; 95% CI [1.18, 8.85]), and compared to NHW women with BMI <25.0. As anticipated, Stage II at

4. Discussion
In our analysis of high grade endometrial carcinomas we ﬁnd that
the number of comorbid conditions, stage at diagnosis, and receiving
NCCN guideline treatment are all associated with overall survival, endometrial cancer survival, and progression-free survival. The interaction of
race and BMI also signiﬁcantly impacts both overall survival and endometrial carcinoma-speciﬁc survival, with NHB women of low BMI
having the highest risk of death even with adjustment for stage at diagnosis and histology. While other endometrial carcinoma studies that include both low and high grade tumors show a strong effect of histology
on survival [18,19], histology had a minimal impact in this analysis
which was restricted to high grade cases.
High BMI has been noted to increase hazard of death of endometrial
cancer patients, especially for women with BMI over 40.0 [20,21,22]. A
2016 meta-analysis of studies on the impact of BMI on high and low
grade endometrial cancer survival found that a 10% increase in BMI
corresponded with a 9.2% increase in the odds of all-cause mortality
[20]. Obesity is a known risk factor for development of all subtypes of
endometrial cancer [3], although it's more closely linked with the
endometrioid subtype than others, possibly due a stronger link between
circulating estrogen levels [5,21]. While studies of the association between BMI and survival in endometrial cancer patients have been
mixed [21,23], most did not consider subtype and race concurrently.
Here, we found that black women with BMI under 25.0 had the highest
hazard of death compared to women of either race with a BMI of 25.0 or
more. Only 12% of NHB women had BMI below 25, so we were unable to
determine how the disease course in these women may differ from their
overweight and obese counterparts. While white women with BMI less
than 25.0 had a survival advantage, black women with BMI less than
25.0 had the poorest overall survival and endometrial cancer survival;
this observed paradox warrants further investigation into this interaction of race and BMI and its effects on survival.
Often coinciding with obesity, comorbidities play a role in endometrial cancer survival and progression, as they do in other cancers [24,25].
As both endometrial cancer and comorbidities are more common
among older people [24], comorbidities impact both treatment options
and survival. A 2017 cohort study found that among over 1000 earlystage endometrial cancer patients, 78% of patients that died within 10
years of surgical treatment (hysterectomy) had a cause of death other
than endometrial cancer [26]. A national report from 2014 found that
40% of cancer patients on Medicare had at least one other chronic condition, and 15% had 2 or more, although this report did not include observations by race [24]. Similarly, in our study population, comorbidities
were present in 40% of NHW patients and 60% of NHB patients. Multiple
studies have reported that patients with comorbidities are less likely to
3
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Table 1
Descriptive statistics for high grade endometrial cancer cases at Henry Ford Hospital and Karmanos Cancer Institute (diagnosed 1997–2017) by race.
Race
Characteristic
Demographics
Age at diagnosis
Mean (Std)
Median (Range)
Age at diagnosis (categories)
<50 years
50–59 years
60–69 years
70+ years
Marital statusb
Never married
Married/Living with Partner
Separated/Divorced/Widowed
Census Tract % in poverty
0–5%
5–10%
10–20%
20–100%
Diagnosis
Stage at diagnosis
I
II
III
Histologic subtype
Clear cell
Endometrioid
Mixed cell
Serous
Medical history
Body mass index
<25.0
>25.0
Comorbidity count
None
1
2
3 or more
Hypertension
Yes
No
NCCN Guideline-Concordant Treatmentc
Yes
No
Adjuvant therapy
None (Surgery only)
Chemo only
Radiation only
Chemo + Radiation
Adjuvant Therapy Lead Timed
<3 Months
≥3, <6 Months
≥6 Months
Vital Status
Living
Dead
Overall survival time
<5 years
5 years or more
Overall survival time (years)e
Median
Endometrial cancer survival
Alive
Death by endometrial cancer
Death by other cause
Recurrence status [1]
No recurrence
Recurrence
Never Disease-free
Progression free survival time (years)e
Median

All (N = 382)

Non-Hispanic White (N = 153)

Non-Hispanic Black (N = 229)

P valuea

63.4 (9.1)
65.0 (48.0)

62.0 (10.0)
64.0 (48.0)

64.3 (8.4)
65.0 (42.0)

0.006

33 (8.6)
80 (20.9)
165 (43.2)
104 (27.2)

20 (13.1)
36 (23.5)
60 (39.2)
37 (24.2)

13 (5.7)
44 (19.2)
105 (45.9)
67 (29.3)

0.01

70 (18.6)
162 (43.1)
144 (38.3)

24 (16.5)
91 (59.9)
36 (23.7)

46 (20.4)
71 (31.6)
108 (48.0)

<0.001

55 (14.4)
52 (13.6)
81 (21.2)
194 (50.8)

47 (30.7)
42 (27.5)
34 (22.2)
30 (19.6)

8 (3.5)
10 (4.4)
47 (20.5)
164 (71.6)

<0.001

201 (52.6)
50 (13.1)
131 (34.3)

85 (55.6)
14 (9.2)
54 (35.3)

116 (50.7)
36 (15.7)
77 (33.6)

0.17

27 (7.1)
144 (37.7)
36 (9.4)
175 (45.8)

10 (6.5)
76 (49.7)
16 (10.5)
51 (33.3)

17 (7.4)
68 (29.7)
20 (8.7)
124 (54.2)

<0.001

60 (17.1)
322 (84.3)

34 (24.5)
119 (77.8)

26 (12.3)
203 (88.7)

0.003

187 (49.3)
102 (26.9)
42 (11.1)
48 (12.7)

94 (61.8)
35 (23.0)
12 (7.9)
11 (7.2)

93 (41.0)
67 (29.5)
30 (13.2)
37 (16.3)

<0.001

282 (74.4)
97 (25.6)

92 (60.5)
60 (39.5)

190 (83.7)
37 (16.3)

<0.001

355 (92.9)
27 (7.1)

140 (91.5)
13 (8.5)

215 (93.9)
14 (6.1)

0.37

101 (26.4)
59 (15.5)
121 (31.7)
101 (26.4)

35 (22.9)
24 (15.7)
54 (35.3)
40 (26.1)

66 (28.8)
35 (15.3)
67 (29.3)
61 (26.6)

0.51

154 (67.3)
52 (22.7)
23 (10.0)

66 (70.2)
19 (20.2)
9 (9.6)

88 (65.2)
33 (24.4)
14 (10.4)

0.52

179 (46.9)
203 (53.1)

82 (53.6)
71 (46.4)

97 (42.4)
132 (57.6)

0.03

177 (46.3)
205 (53.7)

57 (37.3)
96 (62.8)

120 (52.4)
109 (47.6)

0.003

5.7

6.7

4.7

0.002

179 (46.9)
141 (36.9)
62 (16.2)

82 (53.6)
48 (31.4)
23 (15.0)

97 (42.4)
93 (40.6)
39 (17.0)

0.09

230 (61.2)
107 (28.5)
39 (10.4)

103 (69.1)
32 (21.5)
14 (9.4)

127 (56.0)
75 (33.0)
25 (11.0)

0.03

4.9

6.4

3.9

0.03

Abbreviations: NCCN (National Cancer Care Network)
a
calculated with Wilcoxon test for continuous variables, Cochran Armitage test for ordinal variables, Chi squared tests for categorical variables, and median one-way analysis for survival time variables
b
N unknown = 6
c
N unknown = 5
d
Time between hysterectomy date and ﬁrst adjuvant therapy treatment date, N unknown date = 52
e
Calculated with Kaplan Meier
4
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Fig. 1. Overall Survival by Race. Kaplan Meier overall survival for the 382 high grade endometrial carcinoma cases after surgery, by race. Race is an independent predictor of overall survival
in unadjusted analysis (p = 0.0075). Abbreviations: non-Hispanic white (NHW), non-Hispanic black (NHB).

concordant care in our study is higher than what has been reported in
other US study cohorts [27,28].
Previous research on high grade endometrial cancer has had mixed
results regarding the effect of histologic subtype on survival. In particular, the endometrioid subtype has been associated with improved survival compared to other high grade subtypes in a study using data
from all SEER sites, as well as the National Cancer Database [29–31].

receive curative treatment for their cancer, due to factors such as contraindications for treatment [24,25]. Our analysis shows that receipt of
NCCN guideline-concordant treatment is associated with improved
overall survival, disease-speciﬁc survival, and progression-free survival.
We also report no differences in receipt of NCCN guideline-concordant
care by race in our population, all receiving care at high-volume academic institutions. The percentages of women receiving guideline-

Fig. 2. Progression-Free Survival by Race: Kaplan-Meier progression-free survival for the 382 high grade endometrial carcinoma cases after surgery, by race (NHW and NHB). Race is an
independent predictor of progression-free survival in this unadjusted analysis (P = 0.0016). Abbreviations: NHW (non-Hispanic white), NHB (non-Hispanic black).
5

Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
Elsevier on June 18, 2021. For personal use only. No other uses without permission. Copyright ©2021. Elsevier Inc. All rights reserved.

J. Fucinari, M.A. Elshaikh, J.J. Ruterbusch et al.

Gynecologic Oncology xxx (xxxx) xxx

Fig. 3. Overall Survival by Race and BMI. Kaplan-Meier overall survival for the 382 high grade endometrial cancer cases after surgery, by race and BMI (NHW <25.0, NHW 25.0+, NHB
<25.0, NHB 25.0+). The race/BMI interaction is an independent predictor of progression-free survival in this unadjusted analysis (P = 0.024). Abbreviations: NHW (non-Hispanic
white), NHB (non-Hispanic black), BMI (body mass index).

Table 2
Cox proportional hazards models for high grade endometrial cancer survival (diagnosed
1997–2017).

Covariate
Race and BMI
NHW BMI <25.0
NHW BMI 25.0+
NHB BMI <25.0
NHB BMI 25.0+
FIGO stage at diagnosis
Stage I
Stage II
Stage III
Histologic subtype
Endometrioid
Clear Cell
Mixed
Serous
NCCN GCT
Yes
No
Comorbidity count

Model 1.

Model 2.

Death by any cause /
Overall survival

Endometrial cancer death
with competing risk of
death by other cause

HR (95% CI)

P value

HR (95% CI)

Ref
2.17 (1.10, 4.29)
3.03 (1.35, 6.81)
2.43 (1.28, 4.60)

0.03⁎
0.004⁎
0.006⁎

Ref
2.32 (0.93, 5.37)
3.23 (1.18, 8.85)
2.56 (1.10, 5.95)

0.07
0.02⁎
0.03⁎

Ref
1.64 (1.03, 2.63)
3.28 (2.37, 4.53)

0.04⁎
<0.001⁎

Ref
2.44 (1.40, 4.24)
4.52 (3.04, 6.72)

0.002⁎
<0.001⁎

Ref
0.43 (0.21, 0.85)
1.06 (0.62, 1.80)
0.95 (1.01, 0.73)

0.02⁎
0.83
0.95

Ref
0.44 (0.20, 1.01)
1.07 (0.57, 2.01)
1.11 (0.75, 1.64)

0.05
0.84
0.59

Ref
2.52 (1.50, 4.26)
1.23 (1.12, 1.36)

<0.001⁎
<0.001⁎

Ref
3.00 (1.64, 5.47)
1.16 (1.03, 1.31)

<0.001⁎
0.01⁎

Table 3
Cox proportional hazards model for progression-free survival of high grade endometrial
cancer cases (diagnosed 1997–2017).
Covariate

P value

Patient race
NHW
NHB
Stage at diagnosis
I
II
III
Histologic subtype
Endometrioid
Clear Cell
Mixed
Serous
NCCN GCT
Yes
No
Comorbidity count
Body mass index
<25.0
>25.0

Abbreviations: NHW (non-Hispanic white); NHB (non-Hispanic black); BMI (body mass
index); NCCN GCT (National Cancer Care Network Guideline-Concordant Treatment)
⁎ Statistically signiﬁcant at α = 0.05

HR (CI)

P value

Ref
1.40 (1.01, 1.93)

0.05⁎

Ref
1.55 (0.96, 2.49)
2.73 (1.97, 3.79)

0.07
<0.001⁎

Ref
0.57 (0.30, 1.10)
1.14 (0.67, 1.93)
1.14 (0.81, 1.59)

0.10
0.63
0.45

Ref
2.24 (1.26, 4.00)
1.17 (1.06, 1.30)

0.01⁎
0.002⁎

Ref
1.23 (0.81, 1.86)

0.33

Abbreviations: NHW (non-Hispanic white); NHB (non-Hispanic black); NCCN GCT (National Cancer Care Network Guideline-Concordant Treatment
⁎ statistically signiﬁcant at α = 0.05
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A California SEER-based study found that disease-speciﬁc survival in
women with high grade tumors was similar for serous, clear cell, and
endometrioid cancers [32]. Other studies focused on high grade endometrial cancer suggest that the conventional histologic subtyping is
too limited, and that incorporating molecular and genetic markers
into tumor classiﬁcation, along with histologic subtyping and grading
will ultimately provide better insight into prognosis and treatment [33].
Our study has a number of strengths, including the utilization of
both medical records and cancer registry data to focus on high grade endometrial carcinomas. Next, often underrepresented in endometrial
carcinoma research despite historically worse outcomes, 60% of our
study population is NHB, which is representative of the metropolitan
Detroit population served by KCI and HFHS. In addition, with tissue
blocks available, we were able to have each case reviewed by our pathologist for FIGO histologic grade and subtype. Lastly, the retrospective
design of the study allowed for each patient to be followed for at least 5
years, which is sufﬁcient to identify most recurrences and deaths in
women with high grade endometrial carcinomas.
There are limitations that should be noted, including the hospitalbased design that included only women with hysterectomies after an
endometrial carcinoma diagnosis from two urban academic cancer centers. This excluded stage 4 cancers, those who did not receive surgical
treatment, as well as carcinosarcomas, which are also aggressive endometrial cancers. Thus, this limits the generalizability of these results, although the vast majority of women with an endometrial carcinoma
diagnosis receive a hysterectomy. Additionally, while both medical records and death certiﬁcates were reviewed for cause of death, it is possible that endometrial carcinoma-related deaths were underreported
on the death certiﬁcates. Finally, as this was a retrospective analysis,
we were unable to assess some factors that are likely associated with
endometrial carcinoma survival, including access to care, subsequent
treatment, economic status and education, and health behaviors
(e.g., smoking) that may play a role in survival. Prospective work to understand how social determinants of health, medical mistrust, and economic factors, often the result of decades of structural barriers, interact
with biological variables that impact endometrial carcinoma outcomes
is needed to eliminate the current disparities seen in survival in most
population-based studies.
As with many cancers, a focus on primary care and prevention of
chronic conditions can reduce cancer risk and increase odds of survival
if a patient is to develop cancer. Prevention of comorbidities may increase the percentage of patients that are able to receive NCCN
guideline-concordant care, especially important in aggressive cancers
such as these high grade endometrial carcinomas. Additional research
is underway into the genomic landscape of high grade endometrial carcinomas and may provide a variety of targeted therapies that will improve outcomes for all women with these aggressive tumor subtypes.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ygyno.2021.04.036.
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